Lawrence Joseph Wheat: Influence Statistics

Lawrence Joseph Wheat

Lawrence Joseph Wheat

MiraVista Diagnostics, Indianapolis, Indiana, USA | Miravista Diagnostics, LLC, Indianapolis, Indiana, USA. | MiraVista Diagnostics, Indianapolis, Indiana, USA. | MiraVista ...

Lawrence Joseph Wheat: Expert Impact

Concepts for which Lawrence Joseph Wheat has direct influence: Disseminated histoplasmosis , Histoplasma antigen , Capsulatum antigen , Histoplasma capsulatum , Fungal antigens , Antigen detection , Rapid diagnosis .

Lawrence Joseph Wheat: KOL impact

Concepts related to the work of other authors for which for which Lawrence Joseph Wheat has influence: Fungal infections , Disseminated histoplasmosis , Histoplasma capsulatum , Invasive aspergillosis , Central nervous , Immunocompromised patients , Diabetic foot .

KOL Resume for Lawrence Joseph Wheat

Year
2021

MiraVista Diagnostics, Indianapolis, Indiana, USA

2020

MiraVista Diagnostics, Indianapolis, Indiana, USA.

2019

MiraVista Diagnostics, Indianapolis, Indianapolis, Indiana

2018

Department of Medicine, Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana, United States of America

From MiraVista Diagnostics, Indianapolis, Indiana.

2017

MiraVista Diagnostics, Indianapolis, IN, USA

2016

MiraVista Diagnostics, 4705 Decatur Boulevard, Indianapolis, IN 46241, USA

2015

MiraVista Laboratories, Indianapolis, IN, United States of America

2014

University of Michigan Health System, Division of Infectious Diseases (JR, CAK), Ann Arbor, Michigan; Veterans Affairs Ann Arbor Healthcare System (CAK), Ann Arbor, Michigan; University of Wisconsin, Division of Infectious Diseases (JAS), Madison, Wisconsin; University of Kansas School of Medicine (MA), Wichita, Kansas; Sawtooth Infectious Diseases (SB), Boise, Idaho; Idaho Falls Infectious Diseases (MIB), Idaho Falls, Idaho; Stanford University, Division of Infectious Diseases and Geographic Medicine (SD), Palo Alto, California; Vanderbilt University, Division of Infectious Diseases (PWW), Nashville, Tennessee; University of Oklahoma College of Medicine, Division of Infectious Diseases (DAD), Oklahoma City, Oklahoma; Community Infectious Disease (SAN), Indianapolis, Indiana; Mayo Clinic, Division of Infectious Diseases (HRV), Phoenix, Arizona; North Dakota State University, Master of Public Health Program (PJC), Fargo, North Dakota; Mayo Clinic, Division of Infectious Diseases (PV), Rochester, Minnesota; Scott and White Clinic (JC), Texas A&M University College of Medicine, Temple, Texas; Infectious Diseases Specialists (SMS), Dallas, Texas; and MiraVista Diagnostics (LJW), Indianapolis, Indiana.

MiraVista Diagnostics, Indianapolis, Indianapolis, USA

2013

Aspergillus Technology Consortium (AsTeC), Würzburg, Germany

Miravista Diagnostics, Indianapolis, Indiana

2012

MiraVista Diagnostics and MiraBella Technologies, Indianapolis, IN, USA

From the Department of Pediatrics, Indiana University School of Medicine, and Mira Vista Diagnostics, Indianapolis, IN.

2011

MiraVista Diagnostics and MiraBella Technologies, Indianapolis, Indiana

2010

MiraVista Laboratories, Indianapolis, IN

2009

MiraVista Diagnostics/MiraBella Technologies, Indianapolis, IN, USA

Miravista Labs, Indianapolis, Indiana

2008

Roudebush VA Medical Center, Indianapolis, Indiana

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee

2007

MiraVista Diagnostics
 4444 Decatur Blvd., Suite 300
 Indianapolis, Indiana 46241

Mira Vista Diagnostics, Indianapolis, Indiana

2006

MiraVista Diagnostics
 Indianapolis, Indiana

2005

Dr. Mitchell Goldman, Indiana University School of Medicine, Div. of Infectious Diseases, Wishard Memorial Hospital, Rm. OPW-430, 1001 W. 10th St., Indianapolis, IN 46202

Department of Medicine, Division of Gastroenterology and Hepatology, Indiana University Medical Center, Indianapolis, Indiana; Director, MiraVista Diagnostics, Indianapolis, Indiana; Department of Pathology and Laboratory Medicine, Division of Clinical Microbiology Indiana University School of Medicine and Clarian Health Partners, Inc. (Methodist-IU-Riley Hospitals), Indianapolis, Indiana; and Chief of Medicine, Roudebush VA Medical Center, Indianapolis, Indiana

2004

From the *Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, and the †Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA; ‡Shelby County Health Department, Shelbyville, IN; §Indiana State Department of Health and ∥MiraVista Diagnostics, Indianapolis, IN; and the ¶National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Cincinnati, OH

Department of Radiology, Indiana University School of Medicine, Indianapolis, Indiana

2003

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

Associate Editor

Histoplasmosis Reference Laboratory, Indianapolis and

2002

Department of Medicine, Indiana University School of MedicineIndianapolis, Indiana

Histoplasmosis Reference Laboratory

2001

Division of Infectious Diseases, Indiana University School of Medicine, Richard L. Roudebush Department of Veterans' Affairs Hospital, Histoplasmosis Reference Laboratory, Indianapolis, IN 46202-28790, USA.

Department of Medicine, Indiana University School of Medicine

Veterans' Affairs Medical Center,

Histoplasmosis Reference Laboratory, and

2000

Departments of Internal Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA

Department of Pathology and Laboratory Medicine , Indianapolis, Indiana

Roudebusch Veterans' Affairs Medical Center3 and

1998

Division of Infectious Diseases, Indiana University Medical Center, Indianapolis, Indiana

1997

Department of Medicine, Indiana University School of Medicine, Indianapolis 46262, USA.

1995

Division of Infectious Diseases, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA

Prominent publications by Lawrence Joseph Wheat

KOL-Index: 16038 . The effects of prolonged itraconazole exposure on the susceptibility of Candida albicans isolates to itraconazole and fluconazole have not been well characterized. A recent placebo-controlled study of long-term itraconazole antifungal prophylaxis in persons with advanced human immunodeficiency virus infection afforded the opportunity to address this question. Mucosal Candida sp. isolates ...
Known for Candida Albicans | Itraconazole Fluconazole | Vitro Azole Resistance | Immunodeficiency Virus
KOL-Index: 12790 . We review the experience at our institution with galactomannan (GM) testing of bronchoalveolar lavage (BAL) fluid in the diagnosis of invasive pulmonary aspergillosis (IPA) among solid-organ transplant recipients. Among 81 patients for whom BAL GM testing was ordered (heart, 24; kidney, 22; liver, 19; lung, 16), there were five cases of proven or probable IPA. All five patients had BAL GM ...
Known for Bronchoalveolar Lavage | Transplant Recipients | Bal Gm | Specificity Positive Predictive
KOL-Index: 12666 . CONTEXT: Management of antiretroviral treatment failure in patients receiving protease inhibitor (PI)-containing regimens is a therapeutic challenge. OBJECTIVE: To assess whether adding a second PI improves antiviral efficacy of a 4-drug combination in patients with virologic failure while taking a PI-containing regimen. DESIGN: Multicenter, randomized, 4-arm trial, double-blind and ...
Known for Viral Load | Protease Inhibitor | 24 Weeks | Saquinavir Indinavir
KOL-Index: 12483 . Pulmonary aspergillosis in nonimmunocompromised hosts, although rare, is being increasingly recognized. The diagnosis of pulmonary aspergillosis is difficult, since the recovery of Aspergillus from respiratory samples cannot differentiate colonization from invasion. We assessed the role of bronchoalveolar lavage (BAL) in detecting galactomannan (GM) for diagnosing pulmonary aspergillosis ...
Known for Pulmonary Aspergillosis | Bronchoalveolar Lavage | Sensitivity Specificity | Galactomannan Diagnosis
KOL-Index: 12354 . A randomized, open-label, comparative study was conducted in 30 male patients with moderately advanced human immunodeficiency virus (HIV) infection to examine the pharmacokinetics of an investigational intravenous preparation of itraconazole compared with pharmacokinetics after administration of itraconazole capsules. The study also assessed whether adequate plasma concentrations of ...
Known for Intravenous Itraconazole | Plasma Concentrations | Oral Administration | Virus Infection
KOL-Index: 11720 . BACKGROUND: Detection of antigen in BAL is useful for diagnosis of histoplasmosis. The MVista Histoplasma antigen enzyme immunoassay has been modified to permit quantification. The purpose of this study is to compare the sensitivity of the quantitative antigen detection assay with cytopathology and culture of BAL specimens. METHODS: BAL from patients with histoplasmosis who were evaluated ...
Known for Antigen Detection | Patients Histoplasmosis | Bal Fluid | Serum Urine
KOL-Index: 11559 . PURPOSE: Oropharyngeal candidasis (thrush) is the most common opportunistic infection in individuals who are positive for the human immunodeficiency virus (HIV) and those who have progressed to AIDS. Itraconazole has a broad in vitro spectrum of activity, including a wide variety of Candida species. Our study determined the relative efficacy of a new oral solution formulation of ...
Known for Itraconazole Oral Solution | Oropharyngeal Candidiasis | Aids Patients | Fluconazole Treatment
KOL-Index: 11384 . The diagnosis of Histoplasma capsulatum infection by serologic testing for the presence of antibodies is limited by a high rate of false positive and false negative results and by the requirement that the patient have a normal immune response. We have developed a radioimmunoassay for the detection of H. capsulatum antigen in urine and serum specimens. Antigenuria was noted in 20 of 22 ...
Known for Capsulatum Antigen | Disseminated Histoplasmosis | Urine Specimens | 16 Patients
KOL-Index: 10708 . Background: Central nervous system (CNS) histoplasmosis is a life-threatening condition and represents a diagnostic and therapeutic challenge. Isolation of Histoplasma capsulatum from cerebrospinal fluid (CSF) or brain tissue is diagnostic; however, culture is insensitive and slow growth may result in significant treatment delay. We performed a retrospective multicenter study to evaluate ...
Known for Histoplasma Meningitis | Cerebrospinal Fluid | Cns Histoplasmosis | Antibody Csf
KOL-Index: 10429 . PURPOSE: Disseminated histoplasmosis is a serious and often rapidly progressive, opportunistic infection in patients with acquired immunodeficiency syndrome (AIDS), supporting the importance of rapid diagnostic tests. We investigated Histoplasma capsulatum polysaccharide antigen (HPA) detection, a promising new method for rapid diagnosis of histoplasmosis. PATIENTS AND METHODS: Sixty-one ...
Known for Disseminated Histoplasmosis | Patients Aids | Immunodeficiency Syndrome | Hpa Urine
KOL-Index: 10221 . PURPOSE: The purpose of this study was to establish the effect of induction and maintenance treatment with amphotericin B on levels of Histoplasma capsulatum var. capsulatum polysaccharide antigen (HPA) in the urine and blood of patients with acquired immunodeficiency syndrome (AIDS) and disseminated histoplasmosis. PATIENTS AND METHODS: This was a retrospective study of the effect of ...
Known for Histoplasma Capsulatum | Urine Serum | Successful Treatment | Patients Amphotericin
KOL-Index: 10175 . BACKGROUND: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic ...
Known for Consensus Definitions | European Organization | Mycoses Study | Invasive Fungal
KOL-Index: 9565 . We have evaluated the Platelia Aspergillus enzyme immunoassay for detection of galactomannan in bronchoalveolar lavage (BAL) specimens in solid organ transplant patients with aspergillosis. The precision and reproducibility in serum or BAL to which galactomannan was added were similar. Sensitivity was 81.8% in patients with aspergillosis, and specificity was 95.8% in lung transplant ...
Known for Bronchoalveolar Lavage | Aspergillus Galactomannan | Performance Characteristics | Sensitivity Specificity

Key People For Disseminated Histoplasmosis

Top KOLs in the world
#1
Lawrence Joseph Wheat
disseminated histoplasmosis histoplasma capsulatum antigen detection
#2
Carol A Kauffman
fungal infections zoster vaccine endemic mycoses
#3
David S McKinsey
fluconazole therapy hiv treatment histoplasmosis patients
#4
George A Sarosi
disseminated histoplasmosis fungal infections pulmonary blastomycosis
#5
James E Loyd
pulmonary hypertension bmpr2 mutation mediastinal fibrosis
#6
Roger M Des Prez
bacterial endotoxin mediastinal fibrosis apical localization

MiraVista Diagnostics, Indianapolis, Indiana, USA | Miravista Diagnostics, LLC, Indianapolis, Indiana, USA. | MiraVista Diagnostics, Indianapolis, Indiana, USA. | MiraVista Diagnostics | MiraVista Diagnostics, Indianapolis, Indiana USA